OxSonics Launches New Website & Renames as OxSonics Therapeutics
OxSonics’ Cofounder Professor Coussios Presents at the Royal Society
OxSonics to Present at the International Oncolytic Virus Congress 2018
Publication: SonoTran® Doesn’t Affect the Inherent Activity of Oncology Drugs
OxSonics Launches New Website & Renames as OxSonics Therapeutics
Oxford, UK – 7th January 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the launch of its new website and its new name “OxSonics Therapeutics”.
Colin Story, CEO, commented: “OxSonics Therapeutics innovative drug delivery platform is designed to deliver significant therapeutic advantages to those patients most in need, as such, the name ‘OxSonics Therapeutics’ better reflects our values and vision as a company.”
“Because our approach has the major advantage of not requiring any drug modification we can employ a hybrid business model. We will apply our technology to in-market oncology agents but also to collaborate with drug developers under strategic co-development partnerships – our new website provides more information to prospective partners.”
“Our vision as a company is to provide life changing therapies to those facing some of the toughest cancers – those patients with solid tumours. We enter the clinical arena next year where we begin to turn this vision into reality.”
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.
OxSonics’ Cofounder Professor Coussios Presents at the Royal Society
Oxford, UK – 24th October 2018 – OxSonics cofounder and Chief Technology Officer Professor Constantin Coussios is an invited speaker at a scientific meeting of the Royal Society on the subject of “Delivering novel therapies in the 21st century”. Professor Coussios’ talk entitled “Shaken and Stirred: Ultrasound-enhanced Drug Delivery” will include data generated using OxSonics proprietary drug delivery platform SonoTran®. Professor Coussios’ presentation covers the technology that underpins SonoTran, namely that SonoTran works by the mechanical effect of ultrasound, known as acoustic cavitation, and how this is exploited for convective transport of therapeutics into solid tumours. Professor Coussios explains that the SonoTran approach utilises relatively low-intensity ultrasound delivered from a portable device and does not require drug modification or encapsulation. In oncology, sub-micron cavitation-inducing particles co-administered with small-molecule drugs, therapeutic antibodies or viruses are shown to increase both the penetration and total dose delivered to tumours following systemic administration, significantly enhancing their therapeutic efficacy even at a reduced systemic dose.
A link to the scientific meeting is shown here: https://royalsociety.org/science-events-and-lectures/2018/10/tof-delivering-novel-therapies/
– ENDS –
About OxSonics® Limited
OxSonics® was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics® SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran® can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics® is based in Oxford, UK.
For more information please visit: www.oxsonics.com
OxSonics to Present at the International Oncolytic Virus Congress 2018
Oxford, UK – 12th April 2018 – OxSonics co-founder Professor Robert Carlisle is an invited speaker at the 2018 International Oncolytic Virus Congress and will be speaking on the subject of “Enhanced Delivery of Oncolytic Viruses into and Throughout Tumours”. The congress is attended by the world’s leading academic groups and companies developing ground-breaking oncolytic viral therapies. Presentations covering both pre-clinical and numerous clinical stage investigations will be reported at the meeting. Professor Robert Carlisle commented: “The invitation to present at this highly prestigious congress underscores the compelling data that OxSonics and its collaborators have generated to date. Although the SonoTran® platform can be applied to any class of oncology agent, the impact that SonoTran can have on the activity of oncolytic viruses can be most profound where the virus is replicating. In pre-clinical models, the SonoTran platform has been shown to yield up to a 10,000-fold increase in activity by improving the tumour dose and distribution of the virus.”
A link to the congress website is shown here: https://iovc.ada.wats-on.co.uk/Home.aspx
– ENDS –
About OxSonics® Limited
OxSonics® was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics® is based in Oxford, UK.
For more information please visit: www.oxsonics.com
Publication: SonoTran® Doesn’t Affect the Inherent Activity of Oncology Drugs
Oxford, UK – 10th January 2018 – OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today reported that a paper entitled “Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines” was published in the International Journal of Nanomedicine. The publication evidences the fact that ultrasound parameters used to safely and successfully deliver small molecule, antibody and viral-based oncology agents to tumors in preclinical models do not detrimentally impact on the structure or activity of these medicines. Dr. Colin Story, Chief Executive Officer commented: “The findings of these detailed experiments add to the significant body of data underpinning the company’s drug delivery platform, SonoTran®. I would like to thank our collaborators in generating this compelling evidence.”
A link to the publication is provided here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768183/
– ENDS –
About OxSonics® Limited
OxSonics® was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics® SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran® can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics® is based in Oxford, UK.
For more information please visit: www.oxsonics.com